Breaking News Instant updates and real-time market news.

SDRL

Seadrill

$19.70

-0.1 (-0.51%)

, CVRR

CVR Refining

$21.48

0.385 (1.83%)

08:45
08/06/18
08/06
08:45
08/06/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Seadrill (SDRL) 99.63% +12.87, CVR Refining (CVRR) 57.09% +10.95, Cronos Group (CRON) 28.92% +0.24, Aegean Marine (ANW) 28.59% +0.23, GlaxoSmithKline (GSK) 0.35% +0.09, Whiting Petroleum (WLL) 0.44% +0.09, ProShares UltraPro S&P 500 (UPRO) 2.79% +0.06, Synergy Pharmaceuticals (SGYP) 13.11% +0.04, Powershares Loan ETF (BKLN) 0.28% +0.03, and JP Morgan (AMJ) 1.86% +0.03.

SDRL

Seadrill

$19.70

-0.1 (-0.51%)

CVRR

CVR Refining

$21.48

0.385 (1.83%)

CRON

Cronos Group

$5.86

-0.15 (-2.50%)

ANW

Aegean Marine

$2.00

0.13 (6.95%)

GSK

GlaxoSmithKline

$40.82

0.22 (0.54%)

WLL

Whiting Petroleum

$47.23

0.17 (0.36%)

UPRO

Uproar Inc

$53.15

0.7 (1.33%)

SGYP

Synergy Pharmaceuticals

$1.60

-0.03 (-1.84%)

AMJ

American Medical Laboratories Inc

$28.95

0.16 (0.56%)

  • 14

    Aug

  • 19

    Aug

  • 01

    Oct

SDRL Seadrill
$19.70

-0.1 (-0.51%)

06/01/18
GHSC
06/01/18
UPGRADE
Target $18
GHSC
Buy
Ship Finance upgraded to Buy from Neutral at Seaport Global
Seaport Global analyst Magnus Fyhr upgraded Ship Finance (SFL) to Buy with a $18 price target saying risk/reward is increasingly attractive with several potential catalysts developing over the next few months, combined with the Seadrill (SDRL) restructuring already reflected in estimates. Fyhr said the company has ample dry powder to pursue accretive acquisitions and the current backlog provides cash flow visibility and dividend support.
CVRR CVR Refining
$21.48

0.385 (1.83%)

08/02/18
MZHO
08/02/18
INITIATION
Target $27
MZHO
Buy
CVR Refining initiated with a Buy at Mizuho
Mizuho analyst Paul Sankey started CVR Refining with a Buy rating and $27 price target. The analyst sees an "attractive" cash distribution yield of 9%-12% through 2020 given the company's expected improvement in cash flow resulting from wider crude differentials.
07/27/18
TUDR
07/27/18
DOWNGRADE
TUDR
Hold
CVR Refining downgraded to Hold from Buy at Tudor Pickering
07/05/18
GSCO
07/05/18
NO CHANGE
Target $136
GSCO
Buy
Phillips 66 preferred among diversified refiners, says Goldman Sachs
Goldman Sachs analyst Neil Mehta writes that gasoline margins by U.S. refiners have come in below expectations so far this summer amid "elevated refining utilization, high gasoline yield, slowing demand trends, and the lag between higher Brent prices and product realization". In his broader sector research note, the analyst states that Phillips 66 (PSX) is his preferred name among the stocks featuring favorable crude differentials/diversified business mixes rather than merchant refining assets with coastal exposure, keeping his Buy rating and $136 price target on the shares because of the company's premium free cash flow generation. Mehta is also positive on CVR Refining (CVRR) and Delek Holdings (DK) based on their "advantaged crude slates", but remains at a Sell for PBF Energy (PBF) because its East Coast/California/Gulf Coast assets are "less exposed to favorable crude discounts and are more closely tied to product margins".
05/30/18
SBSH
05/30/18
DOWNGRADE
Target $25
SBSH
Neutral
CVR Refining downgraded to Neutral from Buy at Citi
Citi analyst Prashant Rao downgraded CVR Refining (CVRR) to Neutral while raising his price target for the shares to $25 from $22. The exchange offer by CVR Energy (CVI) for CVR Refining units brings the two entities closer to a merger, Rao tells investors in a research note. The analyst no longer sees "compelling enough" upside to justify a Buy rating on CVR Refining.
CRON Cronos Group
$5.86

-0.15 (-2.50%)

05/01/18
ADAM
05/01/18
DOWNGRADE
ADAM
Sell
Cronos Group downgraded to Sell from Hold at Canaccord
04/06/18
MITR
04/06/18
UPGRADE
MITR
Buy
Cronos Group upgraded to Buy from Hold at GMP Securities
GMP Securities analyst Martin Landry upgraded Cronos Group to Buy from Hold.
ANW Aegean Marine
$2.00

0.13 (6.95%)

06/05/18
GHSC
06/05/18
NO CHANGE
GHSC
World Fuel Services could take share from Aegean Marine, says Seaport Global
Seaport Global analyst Kevin Sterling commented on news Aegean Marine (ANW), World Fuel Services' primary competitor in the marine fuel logistics segment, will have to write off $200M of accounts receivables owed to the company. Sterling views this as a "crippling blow" to Aegean Marine as selling bunker fuel is a working capital-intensive business, with receivables being the lifeline and major asset of the company. The analyst said Aegean is "severely weakened" and World Fuel has an opportunity to pick up additional market share, combined with the potential for pricing to have an upward bias.
02/23/18
02/23/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. UPS (UPS) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra saying UPS's capex guidance was worse than even the most bearish expectations. 2. Echo Global (ECHO) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Ravi Shanker saying he believes brokers like Echo deserve a "mid-teens multiple at best" as he thinks the mandate for electronic logging devices, or ELDs, will present a challenge to all brokers. 3. Ardagh Group (ARD) downgraded to Market Perform from Outperform at Wells Fargo with analyst Christopher Manuel saying he analyst now sees "limited capital redeployment options" for Ardagh over the next 24-36 months. 4. Acacia Communications (ACIA) downgraded to Neutral from Buy at MKM Partners and to Hold from Buy at DA Davidson and Needham. 5. Aegean Marine (ANW) downgraded to Hold from Buy at Stifel with analyst Benjamin Nolan saying the company's deal to buy the parent company of Hellenic Environmental Centers "takes the cake" in terms of questionable deals, adding "it is hard to even fathom how any transaction could possibly be worse." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/23/18
STFL
02/23/18
DOWNGRADE
STFL
Hold
Aegean Marine downgraded to Hold from Buy at Stifel
02/23/18
02/23/18
DOWNGRADE
Target $2.5

Hold
Aegean Marine downgraded to Hold on 'indefensible acquisition' at Stifel
As previously reported, Stifel analyst Benjamin Nolan downgraded Aegean Marine to Hold from Buy, saying the company's deal to buy the parent company of Hellenic Environmental Centers "takes the cake" in terms of questionable deals, adding "it is hard to even fathom how any transaction could possibly be worse." Among the reasons he dislikes the deal, he cites the fact Aegean is issuing equity "at the worst possible time...to the one person in the world the company should most avoid dealing with," and that they would be paying "at least 300% more than even a conservative fair value." By giving the founder 20M shares, Nolan thinks Aegean will be able to appoint "friendly" board members who won't rock the boat and "allow shady related party transactions" to continue, he tells investors. The analyst cut his price target on the stock to $2.50 from $8.00.
GSK GlaxoSmithKline
$40.82

0.22 (0.54%)

07/25/18
WELS
07/25/18
NO CHANGE
WELS
Market Perform
Even minor delays can hurt Mylan's generic Advair opportunity, says Wells Fargo
After GlaxoSmithKline (GSK) reported U.S. Advair sales declined 43% at constant currency in Q2, Wells Fargo analyst David Maris commented on the read-through to the generic Advair opportunity being pursued by Mylan (MYL). Given the substantial declines branded Advair faces, he said that "even minor delays" can continue to hurt the potential generic opportunity, adding that he has not seen or been notified of any updates from Mylan on Advair since the company was notified in early June that the FDA planned to issue an official Complete Response Letter related to its application. Maris keeps a Market Perform rating on Mylan shares.
07/11/18
WELS
07/11/18
NO CHANGE
WELS
Drug stocks may not react favorably to Pfizer price rollback, Trump tweets, says Wells Fargo
Wells Fargo analyst David Maris notes that there was widespread media coverage of drug price increases taken recently by several large cap drug companies, with President Trump criticizing Pfizer (PFE) for taking these price increases. On Tuesday, Pfizer confirmed it was rolling back its July drug price increases following a conversation with President Trump, he adds. Maris believes that drug stocks will not react favorably to this news, given the chilling effect this will likely have on others looking to take price increases. Nonetheless, the analyst points out that the price increases taken in July are only a small number of increases taken over the past year or several years, so the impact of the rollback to the healthcare system is insignificant in the big picture. Other publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY) and Sanofi (SNY).
06/28/18
WELS
06/28/18
NO CHANGE
WELS
Wells says Amazon deal, Walgreens results have negative read for drug pricing
After Amazon (AMZN) agreed to acquire online pharmacy PillPack, reportedly for $1B, Wells Fargo analyst David Maris noted that he has long stated that Amazon would enter the pharmacy business and warned about the risk to drug pricing in such a scenario. Maris also noted that Walgreens (WBA) reported its U.S. retail pharmacy comparable store sales fell 1.2% in Q3, adding that retailers tend to push drugmakers on price when they feel pressure and the read-through from its report may be negative for drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/13/18
MSCO
06/13/18
NO CHANGE
MSCO
HHS 'smoke signals' worth noting for drugmakers, says Morgan Stanley
After HHS Secretary Alex Azar spoke at a two-hour Senate hearing, Morgan Stanley analyst David Risinger noted that Azar suggested that U.S. drug pricing needs to move to a system without rebates and said payments from drugmakers to PBMs should be eliminated. In listing four HHS actions that could hurt manufacturers, Risinger pointed out that Azar said he is interested in removing 100% cap on Medicaid rebates; he would like to adjust the Part D protected drug classes so that plans can extract rebates from manufacturers; HHS wants to require manufacturers to disclose drug list prices in TV ads; and HHS is focused on transitioning Part B to lower-priced private sector management. In summary, the analyst said that for drugmakers there was "no fire, but smoke signals worth noting." Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
WLL Whiting Petroleum
$47.23

0.17 (0.36%)

05/23/18
MSCO
05/23/18
UPGRADE
MSCO
Overweight
Whiting Petroleum, Oasis Petroleum upgraded to Overweight at Morgan Stanley
As previously reported, Morgan Stanley analyst Drew Venker upgraded both Whiting Petroleum (WLL) and Oasis Petroleum (OAS), each to Overweight from Equal Weight, citing stronger oil prices, improving capital discipline, and positive momentum in the Bakken play. He raised his price target on Whiting to $71 from $43 and increased his price target for Oasis to $19 from $11. Venker also increased his price targets on several other mid-cap E&Ps, including Antero Resources (AR), Continental Resources (CLR), Diamondback Energy (FANG), Energen (EGN), EQT (EQT), Gulfport (GROR), Parsley (PE), Range Resources (RRC) and Southwestern Energy (SWN).
06/14/18
KLRG
06/14/18
NO CHANGE
Target $64
KLRG
Buy
Whiting Petroleum price target raised to $64 from $53 at KLR Group
KLR Group analyst Gail Nicholson raised her price target for Whiting Petroleum to $64 citing the company's "significant" free cash flow generation over the 2018-2022 timeframe and a positive refinement in her Williston productivity assumption. The analyst keeps a Buy rating on the shares.
07/05/18
RHCO
07/05/18
NO CHANGE
Target $70
RHCO
Buy
Whiting Petroleum price target raised to $70 from $65 at SunTrust
SunTrust analyst Neal Dingmann raised his price target on Whiting Petroleum to $70 and kept his Buy rating citing the company's "strong Bakken differentials" and "successful infill / enhanced completion projects", increasing his cash flow estimates while raising his FY18 EPS view to $2.78 from $2.09. Dingmann notes that these trends make him less concerned over the company's need for delevering and acquisition funds from the proceeds of a potential Redtail sale, even though he warns that investors may punish the stock if that sale falls through.
07/30/18
BARD
07/30/18
NO CHANGE
Target $61
BARD
Outperform
Whiting Petroleum price target raised to $61 from $50 at Baird
Baird analyst Joseph Allman raised his price target on Whiting Petroleum to $61 from $50 as he updated his model for the latest financial and operating data. The analyst said he expects to hear the company update its retail sales process when the company reports this week. Allman said cash flow, capex, free cash flow generation and cash are all growing while its debt declines. Allman reiterated his Outperform rating on Whiting Petroleum shares.
UPRO Uproar Inc
$53.15

0.7 (1.33%)

SGYP Synergy Pharmaceuticals
$1.60

-0.03 (-1.84%)

11/14/17
BTIG
11/14/17
NO CHANGE
Target $7
BTIG
Buy
Synergy Pharmaceuticals price target lowered to $7 from $11 at BTIG
BTIG analyst Timothy Chiang lowered his price target on Synergy Pharmaceuticals to $7, saying the revision reflects the potential risk of need for additional equity funding by late 2018/early 2019. Chiang notes that the company may be able to access $100M early next year as part of its loan agreement with CRG LP, but it must meet market cap and Trulance sales minimum requirements. The analyst keeps his Buy rating on Synergy Pharmaceuticals, saying the company is in position to benefit from increased payer access for Trulance in 2018 and the potential for an expanded treatment indication for IBS-C.
01/05/18
OPCO
01/05/18
DOWNGRADE
OPCO
Perform
Synergy Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Derek Archila downgraded Synergy Pharmaceuticals to Perform citing the "nagging capital overhang." The analyst sees the potential for additional dilutive financing in 2018 saying the company may not be able to qualify for the third and fourth tranches of funding from the CRG deal. Any additional equity offerings may require a meaningful discount to the current stock price, Archila tells investors in a research note.
01/25/18
WELS
01/25/18
NO CHANGE
WELS
Outperform
Ironwood outlook unchanged after Trulance approval, says Wells Fargo
Wells Fargo analyst David Maris said that Synergy Pharmaceuticals (SGYP) received FDA approval for Trulance for the treatment of irritable bowel syndrome with constipation, to add to the drug's existing approval for chronic idiopathic constipation. Ironwood's (IRWD) Linzess was initially approved in 2012 for both IBS-C and CIC, noted Maris, who said he expected Trulance's approval in IBS-C and is not making any changes to his Ironwood model following the news. He believes Trulance was already being used off label in IBS-C to some degree, but will be watching if the new on-label indication impacts market share, he said. Maris keeps an Outperform rating on Ironwood shares.
01/25/18
BTIG
01/25/18
NO CHANGE
Target $7
BTIG
Buy
Synergy funding worries may be overdone, says BTIG
BTIG analyst Timothy Chiang noted that Synergy Pharmaceuticals (SGYP) announced that Trulance received expanded FDA approval for IBS-C, which puts it more on par with market leader Linzess from Ironwood (IRWD) and Allergan (AGN). He sees Trulance benefiting from increased payor access and believes the company will have sufficient cash in order to gain access to a second loan tranche of $100M expected by next month, stating that funding worries may be overdone. Chiang keeps a Buy rating and $7 price target on Synergy shares.
AMJ American Medical Laboratories Inc
$28.95

0.16 (0.56%)

TODAY'S FREE FLY STORIES

TLRD

Tailored Brands

$7.66

-0.41 (-5.08%)

13:05
03/20/19
03/20
13:05
03/20/19
13:05
Options
Tailored Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$29.13

-3.5 (-10.73%)

12:55
03/20/19
03/20
12:55
03/20/19
12:55
Options
Health Insurance Innovations put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DRI

Darden

$108.53

-1.88 (-1.70%)

, CAG

Conagra Brands

$22.72

-0.09 (-0.39%)

12:53
03/20/19
03/20
12:53
03/20/19
12:53
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

DRI

Darden

$108.53

-1.88 (-1.70%)

CAG

Conagra Brands

$22.72

-0.09 (-0.39%)

CMC

Commercial Metals

$15.86

-0.26 (-1.61%)

GIII

G-III Apparel

$34.73

-0.83 (-2.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

  • 21

    Mar

MU

Micron

$39.75

-0.63 (-1.56%)

, WSM

Williams-Sonoma

$56.40

-0.39 (-0.69%)

12:53
03/20/19
03/20
12:53
03/20/19
12:53
Earnings
Notable companies reporting after market close »

Notable companies…

MU

Micron

$39.75

-0.63 (-1.56%)

WSM

Williams-Sonoma

$56.40

-0.39 (-0.69%)

GES

Guess

$22.02

-0.49 (-2.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

  • 28

    May

ULTA

Ulta Beauty

$334.29

0.14 (0.04%)

, AMZN

Amazon.com

$1,775.60

13.15 (0.75%)

12:47
03/20/19
03/20
12:47
03/20/19
12:47
Recommendations
Ulta Beauty, Amazon.com, e.l.f. Beauty, Revlon, Estee Lauder, Coty analyst commentary  »

Amazon risk still…

ULTA

Ulta Beauty

$334.29

0.14 (0.04%)

AMZN

Amazon.com

$1,775.60

13.15 (0.75%)

ELF

e.l.f. Beauty

$9.73

0.495 (5.36%)

REV

Revlon

$19.49

1.47 (8.16%)

EL

Estee Lauder

$158.67

-2.03 (-1.26%)

COTY

Coty

$11.42

-0.08 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 01

    May

  • 28

    May

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$281.08

-1.4 (-0.50%)

12:43
03/20/19
03/20
12:43
03/20/19
12:43
Periodicals
Trump says tariffs on China could last for long period of time »

President Trump, speaking…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$281.08

-1.4 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCE

Spark Therapeutics

$113.52

-0.22 (-0.19%)

12:40
03/20/19
03/20
12:40
03/20/19
12:40
Options
Deal hedge opened in Spark Therapeutics »

Deal hedge opened in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VOD

Vodafone

$19.29

0.07 (0.36%)

, LBTYA

Liberty Global

$26.07

-0.08 (-0.31%)

12:39
03/20/19
03/20
12:39
03/20/19
12:39
Periodicals
EC to issue statement of objections on Vodafone, Liberty deal, Reuters says »

EU antitrust regulators…

VOD

Vodafone

$19.29

0.07 (0.36%)

LBTYA

Liberty Global

$26.07

-0.08 (-0.31%)

LBTYK

Liberty Global

$25.40

-0.06 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$39.81

-0.57 (-1.41%)

, SSNLF

Samsung

$0.00

(0.00%)

12:37
03/20/19
03/20
12:37
03/20/19
12:37
Earnings
Fly Intel: What to watch in Micron's earnings report »

Micron (MU) is scheduled…

MU

Micron

$39.81

-0.57 (-1.41%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 28

    May

VOD

Vodafone

$19.30

0.08 (0.42%)

, LBTYA

Liberty Global

$26.03

-0.12 (-0.46%)

12:35
03/20/19
03/20
12:35
03/20/19
12:35
Periodicals
Breaking Periodicals news story on Vodafone, Liberty Global »

EC to issue statement of…

VOD

Vodafone

$19.30

0.08 (0.42%)

LBTYA

Liberty Global

$26.03

-0.12 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$281.11

-1.37 (-0.48%)

, SPX

S&P 500

$0.00

(0.00%)

12:34
03/20/19
03/20
12:34
03/20/19
12:34
General news
Breaking General news story on SPDR S&P 500 ETF Trust, S&P 500 »

Trump says tariffs to…

SPY

SPDR S&P 500 ETF Trust

$281.11

-1.37 (-0.48%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALLY

Ally Financial

$26.57

-0.29 (-1.08%)

12:30
03/20/19
03/20
12:30
03/20/19
12:30
Options
Aggressive call buy in Ally Financial »

Aggressive call buy in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 18

    Apr

  • 28

    May

MSFT

Microsoft

$117.41

-0.31 (-0.26%)

, NTDOY

Nintendo

$0.00

(0.00%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Periodicals
Former Microsoft exclusive 'Cuphead' coming to Nintendo Switch, Verge says »

Indie video game…

MSFT

Microsoft

$117.41

-0.31 (-0.26%)

NTDOY

Nintendo

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

LB

L Brands

$27.53

-0.665 (-2.36%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Options
L Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 23

    May

NTNX

Nutanix

$39.18

0.405 (1.04%)

12:25
03/20/19
03/20
12:25
03/20/19
12:25
Conference/Events
Nutanix to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 21

    Mar

  • 04

    Apr

  • 09

    Jul

EA

Electronic Arts

$96.97

-0.54 (-0.55%)

, GOOG

Alphabet

$1,206.40

6.69 (0.56%)

12:20
03/20/19
03/20
12:20
03/20/19
12:20
Recommendations
Electronic Arts, Alphabet, Alphabet Class A, Microsoft, Sony analyst commentary at Buckingham »

Buckingham Neutral on…

EA

Electronic Arts

$96.97

-0.54 (-0.55%)

GOOG

Alphabet

$1,206.40

6.69 (0.56%)

GOOGL

Alphabet Class A

$1,210.03

6.9 (0.57%)

MSFT

Microsoft

$117.34

-0.38 (-0.32%)

SNE

Sony

$43.20

-2.3 (-5.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
03/20/19
03/20
12:17
03/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
03/20/19
03/20
12:16
03/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$46.07

-1.09 (-2.31%)

12:15
03/20/19
03/20
12:15
03/20/19
12:15
Options
CBS put volume heavy and directionally bearish »

Bearish flow noted in CBS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

12:15
03/20/19
03/20
12:15
03/20/19
12:15
General news
Oil Action: WTI crude »

Oil Action: WTI crude has…

SQ

Square

$74.18

-2.56 (-3.34%)

12:06
03/20/19
03/20
12:06
03/20/19
12:06
Hot Stocks
Square announces new revamped Square Online Store and Square for retail »

Square announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDP

Fresh Del Monte

$27.47

-0.36 (-1.29%)

12:04
03/20/19
03/20
12:04
03/20/19
12:04
Hot Stocks
Fresh Del Monte announces resignation of CFO »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

AMZN

Amazon.com

$1,778.51

16.06 (0.91%)

, DOMO

Domo

$43.20

-0.76 (-1.73%)

12:02
03/20/19
03/20
12:02
03/20/19
12:02
Hot Stocks
Domo announces integration with Amazon SageMaker »

Domo (DOMO) announced a…

AMZN

Amazon.com

$1,778.51

16.06 (0.91%)

DOMO

Domo

$43.20

-0.76 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 10

    Apr

FDX

FedEx

$172.31

-9.19 (-5.06%)

, GOOGL

Alphabet Class A

$1,212.82

9.69 (0.81%)

12:01
03/20/19
03/20
12:01
03/20/19
12:01
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks have declined in…

FDX

FedEx

$172.31

-9.19 (-5.06%)

GOOGL

Alphabet Class A

$1,212.82

9.69 (0.81%)

GOOG

Alphabet

$1,209.05

9.34 (0.78%)

DIS

Disney

$110.34

0.365 (0.33%)

TFCF

21st Century Fox

$49.61

(0.00%)

NVRO

Nevro

$59.90

15.14 (33.82%)

GIS

General Mills

$49.18

1.94 (4.11%)

TDC

Teradata

$45.31

-3.02 (-6.25%)

SCS

Steelcase

$15.66

-1.825 (-10.44%)

TME

Tencent Music

$16.98

-1.67 (-8.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 20

    Mar

  • 21

    Mar

  • 27

    Mar

  • 01

    Apr

  • 02

    Apr

  • 04

    Apr

  • 11

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 14

    May

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

  • 27

    Oct

CEL

Cellcom Israel

$3.78

-0.29 (-7.13%)

12:00
03/20/19
03/20
12:00
03/20/19
12:00
Hot Stocks
Cellcom Israel falls -7.3% »

Cellcom Israel is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.